With Clinical Trial Supply Worked Out, Kite Focuses On Manufacturing Commercial Product
Executive Summary
The six- to eight-day process of developing its autologous T-cell therapy is being fine-tuned for anticipated commercial launch in 2017, as well as for transferring the process to Europe for production there.